Search

Your search keyword '"Lopez-Hänninen, E."' showing total 155 results
Start Over Author "Lopez-Hänninen, E."
155 results on '"Lopez-Hänninen, E."'

10. CT-gesteuerte Brachytherapie

Author

Anna Stohlmann, Jens Ricke, Chie Hee Cho, Roland Felix, Christian Rosner, M Pech, Alexander Beck, Lopez Hänninen E, Peter Wust, Birgit Spors, M. Werk, and Gero Wieners

Subjects
medicine.medical_specialty, Percutaneous, Bile duct, business.industry, medicine.medical_treatment, Brachytherapy, Ablation, medicine.disease, Asymptomatic, Metastasis, medicine.anatomical_structure, Oncology, Edema, medicine, Radiology, Nuclear Medicine and imaging, Radiology, medicine.symptom, Vein, business
Abstract

PURPOSE To assess safety and efficacy of CT-guided brachytherapy of liver malignancies. PATIENTS AND METHODS 21 patients with 21 liver malignancies (19 metastases, two primary liver tumors) were treated with interstitial CT-guided brachytherapy applying a (192)Ir source. In all patients, the use of image-guided thermal tumor ablation such as by radiofrequency or laser-induced thermotherapy (LITT) was impeded either by tumor size > or = 5 cm in seven, adjacent portal or hepatic vein in ten, or adjacent bile duct bifurcation in four patients. Dosimetry was performed using three-dimensional CT data sets acquired after CT-guided positioning of the brachytherapy catheters. RESULTS The mean tumor diameter was 4.6 cm (2.5-11 cm). The mean minimal tumor dose inside the tumor margin amounted to 17 Gy (12-20 Gy). The proportion of the liver parenchyma exposed to > 5 Gy was 18% (5-39%) of total liver parenchyma minus tumor volume. Nausea and vomiting were observed in six patients after brachytherapy (28%). One patient demonstrated obstructive jaundice due to tumor edema after irradiation of a metastasis adjacent to the bile duct bifurcation. We commonly encountered asymptomatic increases of liver enzymes. Local control rates after 6 and 12 months were 87% and 70%, respectively. CONCLUSION CT-guided brachytherapy is safe and effective. This technique displays broader indications compared to image-guided thermal ablation by radiofrequency or LITT with respect to tumor size or localization.

Published
2004
Full Text
View/download PDF

11. Pankreasläsion unklarer Dignität? Ein prospektiv entwickelter diagnostischer Algorithmus

Author

Böhmig, M, primary, Koch, I, additional, Hintze, RE, additional, Veltzke-Schlieker, W, additional, Hoepffner, N, additional, Müller, HP, additional, Lopez-Hänninen, E, additional, Amthauer, H, additional, Ricke, J, additional, Hosten, N, additional, Langrehr, J, additional, Schink, T, additional, Wernecke, KD, additional, Felix, R, additional, Neuhaus, P, additional, Wiedenmann, B, additional, and Rosewicz, S, additional

Published
2015
Full Text
View/download PDF

17. CT-guided percutaneous core biopsies of pulmonary lesions. Diagnostic accuracy, complications and therapeutic impact.

Author

Lopez Hänninen, E., Vogl, T. J., Ricke, J., Felix, R., and Lopez Hänninen, E

Subjects
*LUNG biopsy, *CHEST (Anatomy), *TOMOGRAPHY
Abstract

Purpose: To evaluate the diagnostic accuracy, complications, and therapeutic impact of CT-guided percutaneous core biopsies of pulmonary lesions.Material and Methods: Seventy-nine patients underwent diagnostic CT-guided percutaneous core biopsies of pulmonary lesions between July 1995 and March 1999. Evaluation included corresponding clinical data, pathologic results, and therapeutic consequences.Results: There were 29 benign and 50 malignant lesions. Percutaneous core biopsy had an overall diagnostic accuracy of 95%. For malignant lesions, core biopsy was positive in 48 patients (sensitivity 96%), and for benign lesions, in 27 (sensitivity 93%). There were no false-positive findings. Pneumothoraces were observed in 19 patients (24%) and 4 of them required a chest drain (5%). There were no hematothoraces or major bleeding complications; however, postinterventional local hemorrhages were observed in 23 patients (29%). No hemoptysis was noted.Conclusion: Percutaneous core biopsies of pulmonary lesions offer excellent diagnostic accuracy for both benign and malignant pulmonary lesions at a low complication rate. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

18. Lebendspende-Lebertransplantation bei hepatozellulärem Karzinom

Author

Jonas, S, Mittler, J, Pascher, A, Theruvath, T, Klupp, J, Langrehr, JM, Lopez-Hänninen, E, Rudolph, B, Neuhaus, P, Jonas, S, Mittler, J, Pascher, A, Theruvath, T, Klupp, J, Langrehr, JM, Lopez-Hänninen, E, Rudolph, B, and Neuhaus, P

Published
2005

21. Cytokine-based biotherapy of gastrointestinal tumors

Author

Axel Schomburg, H. Poliwoda, Jens Atzpodien, Michael P. Manns, Jan Buer, Duensing S, Schüler A, Lopez-Hänninen E, and Hartmut Kirchner

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Carcinoid tumors, Alpha interferon, Multimodality Therapy, Immunotoxin, Internal medicine, Drug Discovery, medicine, Humans, Immunologic Factors, Biological response modifiers, Genetics (clinical), Gastrointestinal Neoplasms, Clinical Trials as Topic, business.industry, Interferon-alpha, Drug Synergism, General Medicine, Immunotherapy, medicine.disease, Cytokine, Immunology, Molecular Medicine, Cytokines, Fluorouracil, business, Colorectal Neoplasms
Abstract

Over the past 20 years the administration of cytokines has emerged as an important fourth modality for the treatment of human cancer. Advances in the field of therapy of gastrointestinal tumors have become a major focus of current research, given the lack of progress of conventional antineoplastic therapy in most of these tumors. Among the heterogeneous group of gastrointestinal malignancies, novel therapeutic strategies have been employed for each individual tumor type, and cytokines (interferon-alpha) have gained an established role in the treatment of advanced carcinoid tumors. Although our understanding of the mechanisms of biological response modification is still limited, further improvement in the management of gastrointestinal malignancies can be expected from multimodality therapy regimens employing cytokines in combination with other biological response modifiers, chemotherapeutic agents, active-specific immunotherapy, and immunotoxin- and radionuclide-conjugated monoclonal antibodies. A wide range of clinical and preclinical studies have been conducted in colorectal carcinoma; however, potential therapeutic benefit of cytokine-based biotherapy has not been fully defined. Therefore, largescale, i.e., multicenter, studies are required to quantify the potential therapeutic effects of cytokines in gastrointestinal tumors.

Published
1994

22. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy

Author

Axel Schomburg, Thomas Menzel, Hartmut Kirchner, Rudolph P, Martin Fenner, Lopez-Hänninen E, A Körfer, Poliwoda H, and J. Atzpodien

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Combination therapy, Injections, Subcutaneous, Alpha interferon, Gastroenterology, Capillary Permeability, Cohort Studies, chemistry.chemical_compound, Lactate dehydrogenase, Internal medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Outpatients, Medicine, Cholinesterases, Humans, Adverse effect, Interferon alfa, Transaminases, Cholinesterase, Aged, Clinical Trials as Topic, biology, L-Lactate Dehydrogenase, business.industry, Bilirubin, Blood Proteins, gamma-Glutamyltransferase, Clinical Enzyme Tests, Middle Aged, Alkaline Phosphatase, Blood proteins, Lipids, Recombinant Proteins, Surgery, Oncology, chemistry, Liver, Toxicity, Interferon Type I, biology.protein, Interleukin-2, Immunotherapy, business, medicine.drug
Abstract

A total of 107 cancer patients were treated with 148 cycles of subcutaneous (SC) immunotherapy employing interleukin-2 (rIL-2) and/or interferon-alpha (rIFN-alpha). The systemic toxicities of SC cytokine therapy were retrospectively evaluated with regard to hepatic and metabolic adverse effects, and compared to adverse effects previously reported upon high- or intermediate-dose intravenous (IV) rIL-2 therapy. Our study cohorts consisted of 15 patients who received SC rIL-2 at doses of 4.8-14.4 million IU/m2/day on 5 days per week for a total of 8 weeks, 20 patients who received rIFN-alpha 2b at 3.0-6.0 million U/m2/day thrice weekly for a total of 6 weeks, and 72 patients who were given SC rIFN-alpha 2b at 6.0 million U/m2/day thrice weekly plus SC rIL-2 at 14.4-18.0 million IU/m2/day on days 1 and 2, followed by 4.8 million IU/m2/day, 5 days per week for 6 consecutive weeks. These treatment regimens were well tolerated in the outpatient setting; no toxic deaths occurred, and none of the patients developed life-threatening toxicity. Upon SC rIL-2/rIFN-alpha combination therapy, we observed mild decreases in plasma protein and albumin levels (mean nadir +/- standard deviation, 67 +/- 5 g/L and 38.8 +/- 3.9 g/L, respectively), minor albeit significant increases in serum total bilirubin levels (mean peak +/- standard deviation, 7.8 +/- 3.1 mumol/L), serum aspartate aminotransferase (25.9 +/- 9.9 U/L), alanine aminotransferase (42.0 +/- 45.9 U/L), alkaline phosphatase (301 +/- 255 U/L), lactate dehydrogenase (230 +/- 64 U/L), gamma-glutamyl transpeptidase (147 +/- 141 U/L) activities and triacylglyceride (2.6 +/- 0.9 mmol/L) concentrations. Cholinesterase activities (mean nadir +/- standard deviation, 42.6 +/- 13.7 kU/L), and serum cholesterol levels (4.4 +/- 0.9 mmol/L) decreased upon SC rIL-2/rIFN-alpha combination therapy. These mild clinical side effects and laboratory changes were in marked contrast to a multitude of dose-limiting and life-threatening adverse reactions described upon IV rIL-2 therapy. It is concluded that low-to intermediate-dose SC rIL-2/rIFN-alpha combination therapy as used in this study, can be given in the outpatient setting with good practicability and excellent safety.

Published
1994

25. Liver resection for metastatic gastric cancer

Author

Thelen, A., primary, Jonas, S., additional, Benckert, C., additional, Lopez-Hänninen, E., additional, Neumann, U., additional, Rudolph, B., additional, Schumacher, G., additional, and Neuhaus, P., additional

Published
2008
Full Text
View/download PDF

32. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease

Author

Denecke, T., primary, Steffen, I., additional, Hildebrandt, B., additional, Rühl, R., additional, Streitparth, F., additional, Lehmkuhl, L., additional, Langrehr, J., additional, Ricke, J., additional, Amthauer, H., additional, and Lopez Hänninen, E., additional

Published
2007
Full Text
View/download PDF

33. Metastasen im Pankreas

Author

Bahra, M., primary, Jacob, D., additional, Langrehr, J.M., additional, Glanemann, M., additional, Schumacher, G., additional, Lopez-Hänninen, E., additional, and Neuhaus, P., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results